Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Jul 29, 2020

The study aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine ChAdOx1 MERS, in humans.ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The Lancet Infectious Diseases

Other news

Cookies help us deliver our services. By using our services, you agree to our use of cookies. What are cookies?